Unfortunately, in this article in the September 2019 issue of the European Respiratory Review, the following sentence in the section Currently available reports and ongoing clinical trials of antifibrotic medications for non-IPF-PF; CTD-ILD; Systemic sclerosis (bottom of page 6) was incorrect.
The SLS II study (phase 3) compares nintedanib to placebo for patients with SSc and associated ILD is ongoing [91, 104].
This sentence has been corrected as follows online:
The SENSCIS study (phase 3) compares nintedanib to placebo for patients with SSc and associated ILD is ongoing [91, 104].
- Copyright ©ERS 2019.
http://creativecommons.org/licenses/by-nc/4.0/
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Vol 28 Issue 154
Table of Contents
“Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.” Bridget F. Collins and Ganesh Raghu. Eur Respir Rev 2019; 28: 190022.
